Page 582 - Read Online

Page 18 of 19 Cordover et al. J Cancer Metastasis Treat 2020;6:45 I http://dx.doi.org/10.20517/2394-4722.2020.101

85. Hua H, Kong QB, Zhang HY, Wang J, Luo T, Jiang YF. Targeting mTOR for cancer therapy. J Hematol Oncol 2019;12:71.
86. Chen D, Lin X, Zhang C, et al. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric
cancer via targeting PI3K/Akt/mTOR pathway. Cell Death Dis 2018;9:123.
87. Soares HP, Ming M, Mellon M, et al. Dual PI3K/mTOR inhibitors induce rapid overactivation of the MEK/ERK pathway in human
pancreatic cancer cells through suppression of mTORC2. Mol Cancer Ther 2015;14:1014-23.
88. Choi HJ, Heo JH, Park JY, et al. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Gynecol Oncol 2019;153:135-48.
89. Eswaran J, Soundararajan M, Kumar R, Knapp S. UnPAKing the class differences among p21-activated kinases. Trends Biochem Sci
2008;33:394-403.
90. Kumar R, Li DQ. PAKs in human cancer progression: from inception to cancer therapeutic to future oncobiology. Adv Cancer Res
2016;130:137-209.
91. Rane CK, Minden A. P21 activated kinase signaling in cancer. Semin Cancer Biol 2019;54:40-9.
92. Liu Y, Xiao H, Tian Y, et al. The pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice. Mol Cancer Res
2008;6:1215-24.
93. Zhou W, Jubb AM, Lyle K, et al. PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. J Pathol
2014;234:502-13.
94. Thillai K, Lam H, Sarker D, Wells CM. Deciphering the link between PI3K and PAK: an opportunity to target key pathways in pancreatic
cancer? Oncotarget 2017;8:14173-91.
95. Chen S, Auletta T, Dovirak O, et al. Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol
Ther 2008;7:1793-802.
96. Dart AE, Box GM, Court W, et al. PAK4 promotes kinase-independent stabilization of RhoU to modulate cell adhesion. J Cell Biol
2015;211:863-79.
97. Kimmelman AC, Hezel AF, Aguirre AJ, et al. Genomic alterations link Rho family of GTPases to the highly invasive phenotype of
pancreas cancer. Proc Natl Acad Sci U S A 2008;105:19372-7.
98. Mahlamäki EH, Kauraniemi P, Monni O, Wolf M, Hautaniemi S, Kallioniemi A. High-resolution genomic and expression profiling
reveals 105 putative amplification target genes in pancreatic cancer. Neoplasia 2004;6:432-9.
99. Begum A, Imoto I, Kozaki K, et al. Identification of PAK4 as a putative target gene for amplification within 19q13.12-q13.2 in oral
squamous-cell carcinoma. Cancer Sci 2009;100:1908-16.
100. Davis SJ, Sheppard KE, Pearson RB, Campbell IG, Gorringe KL, Simpson KJ. Functional analysis of genes in regions commonly
amplified in high-grade serous and endometrioid ovarian cancer. Clin Cancer Res 2013;19:1411-21.
101. Liu Y, Chen N, Cui X, et al. The protein kinase Pak4 disrupts mammary acinar architecture and promotes mammary tumorigenesis.
Oncogene 2010;29:5883-94.
102. He LF, Xu HW, Chen M, et al. Activated-PAK4 predicts worse prognosis in breast cancer and promotes tumorigenesis through activation
of PI3K/AKT signaling. Oncotarget 2017;8:17573-85.
103. Bi Y, Tian M, Le J, et al. Study on the expression of PAK4 and P54 protein in breast cancer. World J Surg Oncol 2016;14:160.
104. Minden A. The pak4 protein kinase in breast cancer. ISRN Oncol 2012;2012:694201.
105. Zhuang T, Zhu J, Li Z, et al. p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha
signaling and restores tamoxifen-sensitivity in breast cancer cells. Oncotarget 2015;6:43853-68.
106. Abo A, Qu J, Cammarano MS, et al. PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and
in the formation of filopodia. EMBO J 1998;17:6527-40.
107. Li X, Minden A. PAK4 functions in tumor necrosis factor (TNF) alpha-induced survival pathways by facilitating TRADD binding to the
TNF receptor. J Biol Chem 2005;280:41192-200.
108. Gnesutta N, Minden A. Death receptor-induced activation of initiator caspase 8 is antagonized by serine/threonine kinase PAK4. Mol Cell
Biol 2003;23:7838-48.
109. Gnesutta N, Qu J, Minden A. The serine/threonine kinase PAK4 prevents caspase activation and protects cells from apoptosis. J Biol
Chem 2001;276:14414-9.
110. Murray BW, Guo C, Piraino J, et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic
signaling and tumor growth. Proc Natl Acad Sci U S A 2010;107:9446-51.
111. Staben ST, Feng JA, Lyle K, et al. Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase
inhibitors. J Med Chem 2014;57:1033-45.
112. Yeo D, Huynh N, Beutler JA, et al. Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation
of P21-activated kinases. Cancer Lett 2014;346:264-72.
113. Ryu BJ, Kim S, Min B, et al. Discovery and the structural basis of a novel p21-activated kinase 4 inhibitor. Cancer Lett 2014;349:45-50.
114. Rane C, Senapedis W, Baloglu E, et al. A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast
cancer tumor growth. Sci Rep 2017;7:42555.
115. Abu Aboud O, Chen CH, Senapedis W, Baloglu E, Argueta C, Weiss RH. Dual and specific inhibition of NAMPT and PAK4 By KPT-
9274 decreases kidney cancer growth. Mol Cancer Ther 2016;15:2119-29.
116. Aboukameel A, Muqbil I, Senapedis W, et al. Novel p21-activated kinase 4 (PAK4) allosteric modulators overcome drug resistance and
stemness in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2017;16:76-87.
117. Fulciniti M, Martinez-Lopez J, Senapedis W, et al. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple